EUCTR2012-001440-22-IT
Active, not recruiting
Not Applicable
A PHASE II TRIAL ON NON-SMALL-CELL LUNG CANCER STEM CELLS SENSITIVITY ASSAY (LUCAS)
Not provided0 sitesAugust 19, 2013
ConditionsHistologically/cytologically confirmed diagnosis of metastatic NSCLC.Possibility to obtain tumor tissue form primary tumor or from an accessible metastatic site, or possibility to collect any neoplastic effusion.Performance status of 0-1 according to ECOG score.Therapeutic area: Diseases [C] - Cancer [C04]
Overview
- Phase
- Not Applicable
- Intervention
- Not specified
- Conditions
- Histologically/cytologically confirmed diagnosis of metastatic NSCLC.Possibility to obtain tumor tissue form primary tumor or from an accessible metastatic site, or possibility to collect any neoplastic effusion.Performance status of 0-1 according to ECOG score.
- Sponsor
- Not provided
- Status
- Active, not recruiting
- Last Updated
- 12 years ago
Overview
Brief Summary
No summary available.
Investigators
Eligibility Criteria
Inclusion Criteria
- •Histologically/cytologically confirmed diagnosis of metastatic NSCLC.
- •Possibility to obtain tumor tissue form primary tumor or from an accessible metastatic site, or possibility to collect any neoplastic effusion.
- •Performance status of 0\-1 according to ECOG score.
- •At least one measurable lesion according to RECIST criteria.
- •At least one previous standard chemotherapy regimen and previous therapy with an EGFR\-TKI if EGFR mutated or crizotinib (or other anti ALK agent) if ALK positive.
- •Adequate hematological, renal and liver functions.
- •Radiological evidence of disease progression to the last anticancer therapy.
- •At least 21 days since the last chemotherapy or any anticancer dose.
- •No concomitant comorbidity potentially interfering with the study.
- •If female: childbearing potential either terminated by surgery, radiation, or menopause, or attenuated by use of approved contraceptive method (intrauterine contraceptive device (IUD), birth control pills, or barrier device) during and for three months after trial
Exclusion Criteria
- •No possibility to obtain tumor tissue or neoplastic effusion.
- •Performance status \>1 according to ECOG score.
- •No measurable lesion(s)
- •Life expectancy less than 3 months.
- •Important comorbidity interfering with the study.
- •Significant alteration of liver, hematological or renal function(s).
- •Brain metastases. Patients with resected brain metastases, or with asimptomatic brain metastases already treated with radiotherapy are eligible if they not need for steroids or antiepilettic drugs.No informed consent form signature
Outcomes
Primary Outcomes
Not specified
Similar Trials
Completed
Phase 2
Phase II study of S-1 for non-small lung cancer after failure of two or three prior chemotherapy regimenson Small Cell Lung Cancer (NSCLC)JPRN-UMIN000003986ational Hospital Organization Asahikawa Medical Cencer40
Active, not recruiting
Phase 2
Radical Resection Vs. Ablative Stereotactic Radiotherapy in Patients With Operable Stage I NSCLCNon-small Cell Lung CancerNCT01753414Radiation Therapy Oncology Group44
Active, not recruiting
Not Applicable
A phase II Clinical Trial to Evaluate Intratumoral Injection of a Depot Formulation of Paclitaxel (DTS-301) as Neoadjuvant Therapy of Patients with Breast CancerInvasive primary breast cancerEUCTR2005-001417-18-HUDIATOS S.A.10
Completed
Phase 2
Clinical Trial of the Safety and Efficacy of the Addition of Ramucirumab to Nab-paclitaxel in Previously Treated Patients With Advanced Non-small Cell Lung Cancer (NSCLC)Non-small Cell Lung CancerNCT02730247Liza Villaruz, MD7
Active, not recruiting
Not Applicable
A Phase II Clinical Trial to Evaluate Intratumoral Injection of a Depot Formulation of Paclitaxel (DTS-301) as Neoadjuvant Therapy of Patients with Breast CancerInvasive primary breast cancerEUCTR2005-001417-18-ATDIATOS S.A.10